These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 18035533)

  • 21. Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma.
    Chen Z; Yang J; Li S; Lv M; Shen Y; Wang B; Li P; Yi M; Zhao X; Zhang L; Wang L; Yang J
    PLoS One; 2017; 12(9):e0182397. PubMed ID: 28863134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches.
    Lobbezoo D; Truin W; Voogd A; Roumen R; Vreugdenhil G; Dercksen MW; van den Berkmortel F; Smilde T; van de Wouw A; van Kampen R; van Riel J; Peters N; Peer P; Tjan-Heijnen VC
    Oncotarget; 2016 May; 7(20):29412-9. PubMed ID: 27121067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive ductal carcinoma with lobular features: a comparison study to invasive ductal and invasive lobular carcinomas of the breast.
    Arps DP; Healy P; Zhao L; Kleer CG; Pang JC
    Breast Cancer Res Treat; 2013 Apr; 138(3):719-26. PubMed ID: 23535842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
    Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
    J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-Mastectomy Radiation Therapy for Invasive Lobular Carcinoma: A Comparative Utilization and Outcomes Study.
    Stecklein SR; Shen X; Mitchell MP
    Clin Breast Cancer; 2016 Aug; 16(4):319-26. PubMed ID: 26943990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
    Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
    Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer.
    Truin W; Voogd AC; Vreugdenhil G; van der Sangen MJ; van Beek MW; Roumen RM
    Breast; 2011 Dec; 20(6):505-9. PubMed ID: 21665471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences in Response and Surgical Management with Neoadjuvant Chemotherapy in Invasive Lobular Versus Ductal Breast Cancer.
    Truin W; Vugts G; Roumen RM; Maaskant-Braat AJ; Nieuwenhuijzen GA; van der Heiden-van der Loo M; Tjan-Heijnen VC; Voogd AC
    Ann Surg Oncol; 2016 Jan; 23(1):51-7. PubMed ID: 25980321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infiltrating lobular carcinoma of the breast: systemic treatment.
    Farese SA; Aebi S
    Breast Dis; 2008-2009; 30():45-52. PubMed ID: 19850995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population.
    Lim ST; Yu JH; Park HK; Moon BI; Ko BK; Suh YJ
    World J Surg Oncol; 2014 Mar; 12():56. PubMed ID: 24621330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of semi-quantitative oestrogen receptor expression on adjuvant endocrine therapy efficacy in ductal and lobular breast cancer - a TEAM study analysis.
    van de Water W; Fontein DB; van Nes JG; Bartlett JM; Hille ET; Putter H; Robson T; Liefers GJ; Roumen RM; Seynaeve C; Dirix LY; Paridaens R; Kranenbarg EM; Nortier JW; van de Velde CJ
    Eur J Cancer; 2013 Jan; 49(2):297-304. PubMed ID: 22954666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Analysis of Oncotype DX Recurrence Scores and Clinicopathologic Characteristics in Invasive Lobular Breast Cancer.
    Felts JL; Zhu J; Han B; Smith SJ; Truica CI
    Breast J; 2017 Nov; 23(6):677-686. PubMed ID: 28097781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?
    Jayasinghe UW; Bilous AM; Boyages J
    Breast J; 2007; 13(5):479-85. PubMed ID: 17760669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lobular Histology Does Not Predict the Need for Axillary Dissection Among ACOSOG Z0011-Eligible Breast Cancers.
    Mamtani A; Zabor EC; Stempel M; Morrow M
    Ann Surg Oncol; 2019 Oct; 26(10):3269-3274. PubMed ID: 31342363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study.
    Jung SY; Jeong J; Shin SH; Kwon Y; Kim EA; Ko KL; Shin KH; Lee KS; Park IH; Lee S; Kim SW; Kang HS; Ro J
    BMC Cancer; 2010 Dec; 10():664. PubMed ID: 21126378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution.
    Tubiana-Hulin M; Stevens D; Lasry S; Guinebretière JM; Bouita L; Cohen-Solal C; Cherel P; Rouëssé J
    Ann Oncol; 2006 Aug; 17(8):1228-33. PubMed ID: 16740599
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive lobular breast cancer: the prognostic impact of histopathological grade, E-cadherin and molecular subtypes.
    Engstrøm MJ; Opdahl S; Vatten LJ; Haugen OA; Bofin AM
    Histopathology; 2015 Feb; 66(3):409-19. PubMed ID: 25283075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histologic grading is an independent prognostic factor in invasive lobular carcinoma of the breast.
    Rakha EA; El-Sayed ME; Menon S; Green AR; Lee AH; Ellis IO
    Breast Cancer Res Treat; 2008 Sep; 111(1):121-7. PubMed ID: 17929165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
    Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
    Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.